ESMO 2024 | Phase I/II trial of dazostinag with or without pembrolizumab in advanced solid tumors
Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses findings from a Phase I/II trial (NCT04420884) of dazostinag, a STING agonist, as monotherapy and in combination with pembrolizumab in advanced solid tumors. Dazostinag showed manageable safety across all dose levels, with common adverse events being fatigue, nausea, and cytokine release syndrome (CRS). Early clinical responses included complete and partial responses in combination therapy, and this novel strategy has potential in earlier lines of therapy or in combination with other checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
